{"id":"W2128083415","doi":"10.1016/s1470-2045(13)70510-2","title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Placebo; Chemoradiotherapy; Clinical endpoint; Internal medicine; Population; Lung cancer; Surgery; Phases of clinical research; Hazard ratio; Cancer; Clinical trial; Oncology; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001239928,0.0003629935,0.001476618,0.0001180661,0.0002105619,0.00005397545,0.0004187261,0.0002079282,0.001659552],"category_scores_gemma":[0.0001264969,0.0002314825,0.000277442,0.0002272158,0.0003277196,0.0001060063,0.0001269726,0.0005731338,0.00005828293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008988513,"about_ca_system_score_gemma":0.0009496404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008858728,"about_ca_topic_score_gemma":0.0006373264,"domain_scores_codex":[0.9973777,0.0001880906,0.0005021088,0.0005138912,0.0003531889,0.001065045],"domain_scores_gemma":[0.9972728,0.001237916,0.0002392615,0.0007342948,0.0002779513,0.0002377458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9244736,0.0004978825,0.0001767278,0.0003841508,0.0008568019,0.00003740787,0.00164553,0.00001617181,0.003207437,0.00001886528,0.06547014,0.003215301],"study_design_scores_gemma":[0.8960482,0.00358879,0.00004652255,0.00005941636,0.0004150043,0.00000575931,0.0003205723,0.0009831968,0.004060821,0.00001776201,0.09421468,0.0002392472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.945483,0.003169167,0.0005948705,0.02004842,0.001673564,0.02065391,0.00008144759,0.0001182908,0.008177314],"genre_scores_gemma":[0.8852832,0.005107578,0.002392628,0.006456194,0.01341065,0.06143029,0.00007886163,0.0002073963,0.02563322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06019984,"threshold_uncertainty_score":0.9992531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08993665752350942,"score_gpt":0.4353921749557403,"score_spread":0.3454555174322309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}